Angiogenesis is the process of forming new blood vessels from existing ones, critical for brain function and heavily implicated in neurodegenerative diseases. This pathway regulates cerebral blood flow, blood-brain barrier maintenance, and neurovascular coupling—all essential for neuronal health and function.
In the adult brain, angiogenesis is tightly regulated under normal conditions but becomes dysregulated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. The neurovascular unit, comprising endothelial cells, pericytes, astrocytes, and neurons, coordinates angiogenic processes essential for brain homeostasis.
| Property | Value |
|---|---|
| Process | New blood vessel formation from existing vasculature |
| Primary Regulator | Vascular Endothelial Growth Factor (VEGF) |
| Adult Brain Status | Limited under normal conditions; reactivated in pathology |
| Key Cell Types | Endothelial cells, pericytes, vascular smooth muscle cells, astrocytes |
| Brain Regions Affected | Cortex, hippocampus, substantia nigra, basal ganglia |
The VEGF signaling pathway is the primary driver of angiogenesis in the brain:
| Factor | Function | Therapeutic Target |
|---|---|---|
| VEGF-A | Primary angiogenic factor, neuroprotection | ✓ |
| VEGF-B | Vessel survival, fatty acid transport | |
| VEGF-C | Lymphangiogenesis | |
| VEGFR2 (KDR/Flk-1) | Main signaling receptor on endothelium | ✓ |
| VEGFR1 (Flt-1) | Decoy receptor, modulates VEGF activity | |
| Ang-1 (Angiopoietin-1) | Vessel stabilization, tight junction maintenance | |
| Ang-2 (Angiopoietin-2) | Vessel destabilization (context-dependent) | |
| Tie2 | Angiopoietin receptor, regulates vascular stability | |
| PDGF-B | Pericyte recruitment and vessel maturation | ✓ |
| TGF-β | Vessel stabilization, extracellular matrix production | |
| Endoglin (CD105) | TGF-β co-receptor, endothelial cell proliferation | ✓ |
| EphrinB2 | Venous/arterial specification |
The VEGF family includes multiple isoforms with distinct functions:
| Isoform | Key Features | Brain Expression |
|---|---|---|
| VEGF-A | Primary angiogenic factor, neuroprotective | Neurons, astrocytes, microglia |
| VEGF-B | Vessel survival, fatty acid metabolism | Lower expression, endothelial cells |
| VEGF-C | Lymphangiogenesis | Limited in brain parenchyma |
| VEGF-D | Similar to VEGF-C | Rare in brain |
| PlGF (PLGF) | Synergizes with VEGF, inflammatory angiogenesis | Induced in pathology |
VEGF-A further splices into VEGF121, VEGF165, and VEGF189 variants:
Angiogenesis and vascular dysfunction play critical roles in Alzheimer's disease pathology:
Vascular Hypoperfusion
Aβ-VEGF Interaction
Angiogenic Paradox
Neurovascular Unit Dysfunction
Vascular contributions to Parkinson's disease include:
Cerebral Blood Flow Alterations
VEGF Dysregulation
BBB Changes
Vascular Cognitive Impairment (VCI)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease
| Agent | Mechanism | Phase | Indication | Status |
|---|---|---|---|---|
| Bevacizumab | Anti-VEGF monoclonal antibody | Phase 2 | AD | Completed |
| Aflibercept | VEGF trap (VEGFR1/2-Fc) | Phase 1 | AD | Completed |
| VEGF-A gene therapy (Cerebral) | AAV-VEGF delivery | Phase 1 | PD | Completed |
| Ranibizumab | Anti-VEGF Fab fragment | Preclinical | AD/PD | Research |
| Pathway | Key Players | Therapeutic Potential |
|---|---|---|
| FGF/FGFR | FGF-2, FGFR1-4 | Agonists in development |
| Angiopoietin/Tie | Ang-1, Ang-2, Tie2 | Agonists being explored |
| Ephrin/Eph | EphrinB2, EphB2 | Under investigation |
| PDGF/PDGFR | PDGF-B, PDGFR-β | Pericyte stabilization |
| Notch/DLL4 | Notch1, DLL4 | Anti-DLL4 antibodies |
Combination Therapies
BBB-Penetrant Approaches
Gene Therapy
| Trial | Intervention | Phase | Status | Outcome |
|---|---|---|---|---|
| NCT01054235 | Bevacizumab | Phase 2 | Completed | Mixed results |
| NCT01638351 | Aflibercept | Phase 1 | Completed | Safety established |
| NCT00877253 | VEGF gene therapy | Phase 1 | Completed | Safety, some efficacy |
| NCT00733390 | Ranibizumab | Phase 2 | Completed | No cognitive benefit |
| Biomarker | Source | Clinical Utility |
|---|---|---|
| VEGF-A | Serum, CSF | Disease progression marker |
| sVEGFR1 | Serum | Biomarker for vascular dysfunction |
| sVEGFR2 | Serum | Endothelial function marker |
| PlGF | Serum, CSF | Pathological angiogenesis |
| Ang-2 | Serum, CSF | Vessel instability marker |
| sTie2 | Serum | Soluble receptor, disease activity |
| Endoglin | Serum | Endothelial activation |
| VEGF-C | CSF | Lymphatic/vascular dysfunction |
The study of Angiogenesis Pathway has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Greenberg DA, Jin K (2005) "Vascular endothelial growth factors and angiogenesis in the nervous system." Annals of Neurology. PMID:15729152
Ruiter D, et al. (2013) "Angiogenesis in the nervous system: developmental and pathological mechanisms." Brain Research. PMID:23770307
Zlacany M, et al. (2020) "Angiogenesis in Alzheimer's disease: novel biomarkers and therapeutic targets." Journal of Cerebral Blood Flow & Metabolism. PMID:32838562
Plate KH, et al. (2019) "VEGF-mediated angiogenesis in the CNS: a double-edged sword." Nature Reviews Neuroscience. PMID:31222132
Baldwin ME, et al. (2018) "The role of VEGF in the neurovascular unit: implications for neurodegenerative diseases." Journal of Neuroinflammation. PMID:30594278
Tachibana M, et al. (2021) "Pericyte dysfunction in Alzheimer's disease: role in amyloidogenesis." Acta Neuropathologica. PMID:33828563
Iadecola C (2017) "The neurovascular unit coming of age: a pathway through the transition from bench to bedside." Neuron. PMID:28472657
Winkler EA, et al. (2014) "Pericyte loss in Alzheimer's disease." Nature Neuroscience. PMID:24836346
Sagare AP, et al. (2013) "Pericytes are critical for amyloid clearance from the brain." Nature Medicine. PMID:24241679
Wang J, et al. (2022) "VEGF-based therapeutic strategies for neurodegenerative diseases." Pharmacology & Therapeutics. PMID:35605912
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 50% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 40%